(MENAFN- GlobeNewsWire - Nasdaq) "Rheumatoid Arthritis Continues to Challenge Medical Science While Driving Growth in the Global Therapeutics Market"

Boston, Oct. 08, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research,“ Therapies for Rheumatoid Arthritis: Technologies and Global Markets ” is projected to increase from $30.2 billion in 2025 to reach $41.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.3% from 2025 through 2030.

This report reviews the global market for rheumatoid arthritis (RA) therapies. It explores treatment options such as non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), corticosteroids, biosimilars, and other emerging therapies, while also examining prescription and over-the-counter sales channels. The analysis spans the regions of North America, Europe, Asia-Pacific, the Middle East and Africa, and South America, with insights into the markets of countries in each region. The report highlights market trends, growth opportunities, and challenges, along with a thorough evaluation of the competitive landscape and regulatory environment. It also provides insights into market segmentation, leading players' market shares, and the factors driving or restraining market growth.

This report is highly relevant today because the treatment landscape for rheumatoid arthritis is undergoing major changes. With new therapies like targeted biologics, biosimilars, and small molecule inhibitors emerging, staying informed is essential for improving patient care. The shift toward personalized medicine means understanding the safety and effectiveness of each therapy is key to tailoring treatments to individual needs. At the same time, rising concerns about drug pricing and access make it important to evaluate the cost-effectiveness of available options. This report helps healthcare professionals and decision-makers navigate these developments to ensure better outcomes and more sustainable treatment strategies.

The factors driving the market's growth include:

Availability of Biosimilars for RA Treatment: The growing availability of biosimilars, which are affordable alternatives to branded biologics, is driving the RA therapy market. These drugs reduce treatment costs, increase patient access, and promote competition, which encourages innovation and price reductions across the board. Regulatory support is also making it easier for biosimilars to enter the market.

Rising Cases of RA: The number of people diagnosed with rheumatoid arthritis is steadily increasing due to lifestyle factors like smoking, obesity, and sedentary habits, along with improved diagnostic capabilities. As RA is a chronic condition, more patients require long-term treatment, which boosts demand for both traditional and advanced therapies.

Increasing Aging Population: RA is more common in older adults, and with the global population aging rapidly, the number of people affected is rising. Older individuals often need ongoing and specialized care, which increases the demand for safer, more effective, and personalized RA treatments.

Request a sample copy of the global market for rheumatoid arthritis therapies reports .

Report Synopsis

Report Metric	Details
Base year considered	2024
Forecast period considered	2025-2030
Base year market size	$28.5 billion
Market size forecast	$41.1 billion
Growth rate	CAGR of 6.3% for the forecast period of 2025-2030
Segments covered	Product Type, Cancer Type, Region
Regions covered	North America, Europe, Asia-Pacific, South America, Rest of the World
Countries covered	U.S., Canada, Mexico, U.K., France, Italy, Germany, Spain, Austria, Denmark, the Netherlands, Poland, Sweden, Switzerland, Turkey, China, India, Japan, Australia, South Korea, Malaysia, New Zealand, Singapore, Thailand, Vietnam, Brazil, Argentina, Colombia, Paraguay, Peru
Market Drivers	Increasing Biosimilars for RA Treatment Rising Cases of RA Increasing Aging Population

Interesting fact:

• RA treatment is evolving toward precision and long-term disease control: The focus has shifted from simply managing symptoms to achieving minimal disease activity, reducing inflammation and pain, preventing joint damage, and slowing disease progression. This reflects a more advanced and patient-centered approach to care.

• Innovation and investment are fueling market growth: Biosimilars and JAK inhibitors are expanding treatment options and accessibility. At the same time, pharmaceutical companies are investing in cutting-edge research like gene therapy and personalized medicine to develop safer and more effective RA therapies.

The report addresses the following questions:

What are the projected size and growth rate of the market?

• The global market for therapies for rheumatoid arthritis was valued at $28.5 billion in 2024 and is projected to reach $41.1 billion by the end of 2030, at a CAGR of 6.3% for the forecast period.

What factors are driving the growth of the market?

• The driving factors are the increasing aging population, biosimilars a cost-effective biologic alternative, and rising cases of rheumatoid arthritis.

What are the challenges and opportunities of the market?

• The restraining factors that hamper the RA market include loss of patent exclusivity, shortage of rheumatologists, and side effects of rheumatoid arthritis drugs. The opportunities in the market include technological advances in rheumatoid arthritis, increasing organic strategies among market players, and emerging JAK inhibitors.

Which market segments are covered in the report?

• The market scope in this report is segmented into therapies, including NSAIDs, DMARDs, steroids/corticosteroids, biosimilars, and others. Based on sales channels, the market is segmented into over the counter (OTC) and prescription.

Which therapy type segment will be dominant through 2030?

• NSAIDs currently dominate the market, but the use of biosimilars will show strong growth in the market for rheumatoid arthritis therapies.

Which region has the largest market share?

• The North American market for therapies for rheumatoid arthritis was valued at $15.5 billion in 2024 and is expected to reach $22.4 billion in 2030, at a CAGR of 6.4% during the forecast period.

Market leaders include:

• ABBOTT
• ABBVIE INC.
• AMGEN INC.
• BAYER AG
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC.
• JOHNSON & JOHNSON
• LILLY
• PFIZER INC.
• SANOFI
• SWEDISH ORPHAN BIOVITRUM AB
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• VIATRIS INC .

Purchase a copy of the report direct from BCC Research.

For further information on any of these reports or to make a purchase, contact ....

About BCC Research

BCC Research market research reports provide objective, unbiased measurement, and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.

For media inquiries, email ... or visit our media page for access to our market research library.

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

CONTACT: BCC Research Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: ... Phone: +1 781-489-7301

MENAFN08102025004107003653ID1110168647